nafamostat has been researched along with Blood Clot in 14 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| " The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding." | 7.78 | The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. ( Baek, NN; Huh, W; Jang, HR; Kim, DJ; Kim, YG; Lee, JE; Oh, HY, 2012) |
| " However, patients with bleeding risk and/or heparin-related side effects may necessitate alternative strategies: among these, nafamostat mesilate (NM) has been reported." | 5.22 | Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review. ( Astuto, M; Brancati, S; Currò, JM; Dezio, V; La Via, L; Martucci, G; Murabito, P; Pappalardo, F; Sanfilippo, F, 2022) |
| " The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding." | 3.78 | The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. ( Baek, NN; Huh, W; Jang, HR; Kim, DJ; Kim, YG; Lee, JE; Oh, HY, 2012) |
| "Nafamostat mesilate provided sufficient filter survival without causing major bleeding complications despite the prolongation of APTT." | 3.77 | Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. ( Hosoya, T; Maruyama, Y; Takinami, M; Uchino, S; Yamamoto, H; Yokoyama, K; Yoshida, H, 2011) |
| "Multiple hemorrhagic cerebral infarctions were recognized on a computed tomographic (CT) scan." | 1.39 | Left atrium ball thrombus in a patient with hemorrhagic cerebral infarction. ( Machida, D; Masuda, M; Matsuki, Y; Okamoto, H; Tokunaga, S; Yasuda, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Sanfilippo, F | 1 |
| Currò, JM | 1 |
| La Via, L | 1 |
| Dezio, V | 1 |
| Martucci, G | 1 |
| Brancati, S | 1 |
| Murabito, P | 1 |
| Pappalardo, F | 1 |
| Astuto, M | 1 |
| Yasuda, S | 1 |
| Tokunaga, S | 1 |
| Matsuki, Y | 1 |
| Okamoto, H | 1 |
| Machida, D | 1 |
| Masuda, M | 2 |
| Maruyama, Y | 1 |
| Yoshida, H | 1 |
| Uchino, S | 1 |
| Yokoyama, K | 1 |
| Yamamoto, H | 1 |
| Takinami, M | 1 |
| Hosoya, T | 1 |
| Baek, NN | 1 |
| Jang, HR | 1 |
| Huh, W | 1 |
| Kim, YG | 1 |
| Kim, DJ | 1 |
| Oh, HY | 1 |
| Lee, JE | 1 |
| Sekido, H | 1 |
| Matsuo, K | 1 |
| Takeda, K | 1 |
| Morioka, D | 1 |
| Kubota, T | 2 |
| Tanaka, K | 3 |
| Endo, I | 1 |
| Togo, S | 1 |
| Shimada, H | 1 |
| Kaminishi, Y | 1 |
| Hiramatsu, Y | 1 |
| Watanabe, Y | 1 |
| Yoshimura, Y | 1 |
| Sakakibara, Y | 1 |
| Sawaki, D | 1 |
| Otani, Y | 1 |
| Kobayakawa, N | 1 |
| Sekita, G | 1 |
| Fukushima, K | 1 |
| Takeuchi, H | 1 |
| Ogawa, T | 1 |
| Takemura, T | 1 |
| Aoyagi, T | 1 |
| Borawski, J | 1 |
| Takano, H | 1 |
| Miyamoto, Y | 1 |
| Kaneko, M | 1 |
| Matsuwaka, R | 1 |
| Kuratani, T | 1 |
| Amemiya, A | 1 |
| Nakano, S | 1 |
| Matsuda, H | 1 |
| Morishita, K | 1 |
| Inoue, S | 1 |
| Baba, T | 1 |
| Sakata, J | 1 |
| Kazui, T | 1 |
| Abe, T | 1 |
| Isogai, E | 1 |
| Isogai, H | 1 |
| Kimura, K | 1 |
| Hayashi, S | 1 |
| Fujii, N | 1 |
| Takeshi, K | 1 |
| Sato, T | 1 |
| Kondo, C | 1 |
| Yada, I | 1 |
| Yuasa, H | 1 |
| Kusagawa, M | 1 |
| Nasu, M | 1 |
| Okada, Y | 1 |
| Shomura, T | 1 |
| Matsuo, T | 1 |
| Matsuo, M | 1 |
| Ouga-Maruyama, S | 1 |
| Fukamachi, K | 1 |
| Matsuzaki, K | 1 |
| Asou, T | 1 |
| Toshima, Y | 1 |
| Kinoshita, K | 1 |
| Mayumi, H | 1 |
| Tominaga, R | 1 |
| Miyamoto, K | 1 |
| Komori, M | 1 |
2 reviews available for nafamostat and Blood Clot
| Article | Year |
|---|---|
Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review.
Topics: Anticoagulants; Extracorporeal Membrane Oxygenation; Hemorrhage; Heparin; Humans; Retrospective Stud | 2022 |
Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin.
Topics: Anticoagulants; Atherosclerosis; Benzamidines; Biocompatible Materials; Biomarkers; Blood Vessels; E | 2006 |
2 trials available for nafamostat and Blood Clot
| Article | Year |
|---|---|
Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Topics: Aged; Aprotinin; Benzamidines; Cardiopulmonary Bypass; Dose-Response Relationship, Drug; Drug Therap | 2004 |
Our distal aortic perfusion system in descending thoracic and thoracoabdominal aortic aneurysm repairs.
Topics: Analysis of Variance; Anticoagulants; Antithrombins; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Th | 1997 |
10 other studies available for nafamostat and Blood Clot
| Article | Year |
|---|---|
Left atrium ball thrombus in a patient with hemorrhagic cerebral infarction.
Topics: Aged; Anticoagulants; Benzamidines; Cardiac Surgical Procedures; Cerebral Hemorrhage; Cerebral Infar | 2013 |
Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Benzamidines; Cr | 2011 |
The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Female; Fibrinolysin; Follow-Up Studies; Guanidin | 2012 |
Successful adult ABO-incompatible liver transplantation: therapeutic strategy for thrombotic microangiopathy is the key to success.
Topics: ABO Blood-Group System; Benzamidines; Blood Group Incompatibility; Female; Guanidines; Humans; Liver | 2003 |
A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure--first autopsy report on Japan--.
Topics: Aged; Aged, 80 and over; Antibodies; Benzamidines; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; | 2004 |
[Experimental study on heparin-free cardiopulmonary bypass using nafamostat mesilate (FUT-175) and heparin-coated circuit].
Topics: Animals; Benzamidines; Blood Coagulation Tests; Cardiopulmonary Bypass; Guanidines; Heparin; Platele | 1993 |
Role of tumor necrosis factor alpha in gnotobiotic mice infected with an Escherichia coli O157:H7 strain.
Topics: Animals; Bacterial Toxins; Benzamidines; Brain; Colon; Colony Count, Microbial; Edema; Escherichia c | 1998 |
Hematological problems during the use of cardiac assist devices: clinical experiences in Japan.
Topics: Aged; Anticoagulants; Antithrombin III; Benzamidines; Blood Coagulation; Female; Fibrinopeptide A; G | 1992 |
Can nafamostat mesilate be used for temporary management of hemodialysis in a patient with heparin-induced thrombocytopenia (HIT)?
Topics: Anticoagulants; Benzamidines; Guanidines; Heparin; Humans; Male; Middle Aged; Platelet Activation; P | 2001 |
[Clinical assessment of anticoagulation therapy during left ventricular assist with artificial heart: induction with protease inhibitor].
Topics: Aged; Assisted Circulation; Benzamidines; Drug Evaluation; Drug Therapy, Combination; Gabexate; Guan | 1989 |